Why the study?
Does nebivolol 5 mg once daily reduce blood pressure and improve quality of life in patients with hypertension?
Does nebivolol 5 mg once daily reduce blood pressure and improve quality of life in patients with hypertension?
Nebivolol 5 mg once daily is an effective and well-tolerated antihypertensive agent that does not impair patient quality of life.
Answers are grounded in this paper and cite their sources.
Supports nebivolol 5 mg daily for hypertension; confirms BP-lowering efficacy with high response rates.
Nebivolol is a selective beta 1-adrenoceptor antagonist with a particular hemodynamic profile, suggesting an ancillary vasodilating property. The nature of this ancillary property is still unknown. The present double-blind placebo-controlled multicenter study investigated the effect of 4 and 8 weeks treatment with nebivolol 5 mg once daily on blood pressure (BP), heart rate (HR), blood parameters, and ECG. The effect on quality of life perception and the adverse effect profile were also studied. Nebivolol 5 mg once daily had a good antihypertensive effect in supine (10/8 mm Hg) as well as in standing position (16/10 mm Hg). Of 114 patients studied, 65% had either normalization of or > 10% reduction in diastolic BP (DBP). No evidence of drug tolerance was observed during the 8-week treatment period. Quality of life perception, as measured with the Inventory of Subjective Health (ISH) and the perceived health rating scale, was not impaired with nebivolol during the entire 8-week study. Nebivolol showed a favorable adverse effect profile and appeared to be devoid of central nervous system (CNS) adverse effects. The total number of complaints with nebivolol treatment did not differ from the number of complaints with placebo treatment. ECG and blood analyses, also show that nebivolol is safe and well tolerated. This study also shows that absolute drug-induced changes in quality of life perception can be assessed only in a placebo-controlled study and that comparison with baseline might be incorrect and misleading.
No takes yet. Share an insight, caveat, or question.
Bortel et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: